Research Topic

IBD Management - Novel Targets and Therapeutic Perspectives

  • Submission closed.

About this Research Topic

Inflammatory bowel diseases (IBDs), comprising ulcerative colitis (UC) and Crohn’s disease (CD), are chronic, progressive immune mediated diseases, with a clinical course characterized by remission and relapse. IBDs affect an estimated 1.5 million Americans, 2.2 million people in Europe, and more than several ...

Inflammatory bowel diseases (IBDs), comprising ulcerative colitis (UC) and Crohn’s disease (CD), are chronic, progressive immune mediated diseases, with a clinical course characterized by remission and relapse. IBDs affect an estimated 1.5 million Americans, 2.2 million people in Europe, and more than several hundred thousand worldwide. The chronic nature of these diseases exerts a major toll on patients in terms of burden of therapy, hospitalizations, surgery, health-related quality of life, economic productivity and social functioning.

Against the high and increasing rate of IBD occurrence, a large body of evidence highlights the scarce efficacy of traditional drugs (including corticosteroids, immunosuppressants and salycilates): from 40% to 60% of IBD patients does not benefit of the available traditional therapeutical options, which are characterized also by severe adverse effects. In addition, the novel therapeutic options, based on treatments with biotechnological drugs, are characterized by a very poor profile of tolerability. Overall, the pharmacological therapies available for treatment of IBDs are far from being satisfactory, and intensive efforts are currently in progress to search for new drugs endowed with favourable benefit/risk profiles.
This Research Topic will highlight the most recent advances, obtained either in preclinical and clinical settings, in terms of novel molecular targets and/or innovative strategies (comprising new pharmacological tools, prebiotic and /or probiotic treatments, dietary supplements) useful for the management of several pathological aspects affecting IBD patients, such as intestinal inflammation, neuromuscular and secretive/absorptive intestinal disorders, and visceral pain. Particular attention will be dedicated also to the available evidence regarding the safety of drugs currently employed for IBD treatment. To pursue these goals, the present Research Topic will include both full length and short research communications, as well as opinion and review articles.


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

Submission closed.

Participating Journals

Loading..

Topic Editors

Loading..

Submission Deadlines

Submission closed.

Participating Journals

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..

Comments

Loading..

Add a comment

Add comment
Back to top
);